疑难病杂志
疑難病雜誌
의난병잡지
JOURNAL OF DIFFICULT AND COMPLICATED CASES
2014年
6期
625-626,633
,共3页
钱玉红%李争%王敏%范志媛%张淋淋%史俊玲
錢玉紅%李爭%王敏%範誌媛%張淋淋%史俊玲
전옥홍%리쟁%왕민%범지원%장림림%사준령
芪苈强心胶囊%心力衰竭,慢性%阿霉素%大鼠
芪藶彊心膠囊%心力衰竭,慢性%阿黴素%大鼠
기력강심효낭%심력쇠갈,만성%아매소%대서
Qiliqiangxin capsule%Heart failure,chronic%Adriamycin%Rats
目的:观察芪苈强心胶囊对慢性心力衰竭( CHF )模型大鼠血清超氧化物歧化酶( SOD )、丙二醛( MDA)水平的影响。方法 Wistar大鼠40只,随机抽取8只作为健康对照组,其余大鼠用多次间断腹腔注射阿霉素(ADR)的方法来建立大鼠CHF模型。造模成功后,随机分为模型组和芪苈强心胶囊组(0 j.6 g· kg-1· d-1),每组15只,健康对照组和模型组灌胃等容积的蒸馏水。4周后,各组大鼠称质量,取心脏称质量,计算心脏指数,腹主动脉取血测MDA、SOD水平及血清脑钠肽(BNP)水平。结果与健康对照组比较,模型组大鼠心脏指数[(3.76±0.22)g/kg vs.(2.69±0.25)g/kg]、BNP[(657±59)pg/ml vs.(203±31) pg/ml]水平均明显升高( P <0.05),而芪苈强心胶囊组分别为(3.18±0.15)g/kg和(554±43)pg/ml,均明显低于模型组,差异有统计学意义( P <0.05)。与健康对照组比较,模型组血清SOD水平明显下降[(113.33±10.78) U/ml vs.(197.67±12.93) U/ml],MDA 水平明显升高[(18.72±1.79) nmol/ml vs.(7.73±1.53) nmol/ml],差异有统计学意义( P <0.05),而芪苈强心胶囊组SOD水平(151.17±12.19)U/ml明显高于模型组,MDA水平(14.61±1.27)nmol/ml明显低于模型组,差异均有统计学意义(P <0.05)。结论芪苈强心胶囊对慢性心力衰竭大鼠氧化损伤有治疗作用,其作用机制可能与清除氧自由基,抗脂质过氧化有关。
目的:觀察芪藶彊心膠囊對慢性心力衰竭( CHF )模型大鼠血清超氧化物歧化酶( SOD )、丙二醛( MDA)水平的影響。方法 Wistar大鼠40隻,隨機抽取8隻作為健康對照組,其餘大鼠用多次間斷腹腔註射阿黴素(ADR)的方法來建立大鼠CHF模型。造模成功後,隨機分為模型組和芪藶彊心膠囊組(0 j.6 g· kg-1· d-1),每組15隻,健康對照組和模型組灌胃等容積的蒸餾水。4週後,各組大鼠稱質量,取心髒稱質量,計算心髒指數,腹主動脈取血測MDA、SOD水平及血清腦鈉肽(BNP)水平。結果與健康對照組比較,模型組大鼠心髒指數[(3.76±0.22)g/kg vs.(2.69±0.25)g/kg]、BNP[(657±59)pg/ml vs.(203±31) pg/ml]水平均明顯升高( P <0.05),而芪藶彊心膠囊組分彆為(3.18±0.15)g/kg和(554±43)pg/ml,均明顯低于模型組,差異有統計學意義( P <0.05)。與健康對照組比較,模型組血清SOD水平明顯下降[(113.33±10.78) U/ml vs.(197.67±12.93) U/ml],MDA 水平明顯升高[(18.72±1.79) nmol/ml vs.(7.73±1.53) nmol/ml],差異有統計學意義( P <0.05),而芪藶彊心膠囊組SOD水平(151.17±12.19)U/ml明顯高于模型組,MDA水平(14.61±1.27)nmol/ml明顯低于模型組,差異均有統計學意義(P <0.05)。結論芪藶彊心膠囊對慢性心力衰竭大鼠氧化損傷有治療作用,其作用機製可能與清除氧自由基,抗脂質過氧化有關。
목적:관찰기력강심효낭대만성심력쇠갈( CHF )모형대서혈청초양화물기화매( SOD )、병이철( MDA)수평적영향。방법 Wistar대서40지,수궤추취8지작위건강대조조,기여대서용다차간단복강주사아매소(ADR)적방법래건립대서CHF모형。조모성공후,수궤분위모형조화기력강심효낭조(0 j.6 g· kg-1· d-1),매조15지,건강대조조화모형조관위등용적적증류수。4주후,각조대서칭질량,취심장칭질량,계산심장지수,복주동맥취혈측MDA、SOD수평급혈청뇌납태(BNP)수평。결과여건강대조조비교,모형조대서심장지수[(3.76±0.22)g/kg vs.(2.69±0.25)g/kg]、BNP[(657±59)pg/ml vs.(203±31) pg/ml]수평균명현승고( P <0.05),이기력강심효낭조분별위(3.18±0.15)g/kg화(554±43)pg/ml,균명현저우모형조,차이유통계학의의( P <0.05)。여건강대조조비교,모형조혈청SOD수평명현하강[(113.33±10.78) U/ml vs.(197.67±12.93) U/ml],MDA 수평명현승고[(18.72±1.79) nmol/ml vs.(7.73±1.53) nmol/ml],차이유통계학의의( P <0.05),이기력강심효낭조SOD수평(151.17±12.19)U/ml명현고우모형조,MDA수평(14.61±1.27)nmol/ml명현저우모형조,차이균유통계학의의(P <0.05)。결론기력강심효낭대만성심력쇠갈대서양화손상유치료작용,기작용궤제가능여청제양자유기,항지질과양화유관。
Objective To observe Qiliqiangxin capsule on chronic heart failure rat model serum level of superoxide dismutase (SOD), malondialdehyde (MDA).Methods Forty Wistar rats were randomly selected 8 as healthy control group, the other rats by using several intermittent intraperitoneal injection of adriamycin ( ADR) method to establish a rat model of CHF.After the success of modeling , they were randomly divided into model group and Qiliqiangxin capsule group (0.6 g· kg-1· d-1) with 15 rats in each group, health control group and model group were administered with iso-volume of distilled water.After 4 weeks, the rats weight and heart mass were recorded , cardiac index, abdominal aortic blood MDA, SOD levels and serum brain natriuretic peptide levels of BNP were measured and recorded .Results Compared to the control group, cardiac index of the rats in the model group [(3.76 ±0.22) g/kg vs.(2.69 ±0.25) g/kg], BNP [(657 ±59) pg/ml vs.(203 ±31) pg/ml] levels were significantly elevated ( P <0.05), and Qiliqiangxin capsule group were (3.18 ± 0.15) g/kg and (554 ±43) pg/ml, were significantly lower than those in the model group , the difference was statistically significant ( P <0.05).Compared with the healthy control group , levels of serum SOD model group decreased significantly [(113.33 ±10.78) U/ml vs.(197.67 ±12.93) U/ml], MDA levels were significantly higher [(18.72 ±1.79 )nmol/ml vs.(7.73 ±1.53) nmol/ml], the difference was statistically significant ( P <0.05) and Qiliqiangxin capsule group SOD (151.17 ±12.19) U/ml was significantly higher than the model group , the levels of MDA (14.61 ±1.27) nmol/ml was significantly lower than that in the model group , the differences were statistically significant ( P <0.05).Conclusion Qiliqiangxin capsule has a therapeutic effect on chronic heart failure rats .The mechanism may be related to scavenging oxygen free radicals and inhibiting lipid per oxidation .